Market cap
₹3,800 Cr
Recently Viewed
Clear AllNSE: RPGLIFE | BSE: 532983
₹2,295.00
₹264.50
(13.03%)
As on 30-Apr-2026IST
Market cap
₹3,800 Cr
Revenue (TTM)
₹708 Cr
P/E Ratio
33
P/B Ratio
--
Div. Yield
1 %
Quality Score
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
₹115 Cr
ROE
40.5 %
ROCE
51.8 %
Industry P/E
36.61
EV/EBITDA
--
Debt to Equity
0
Book Value
₹366
EPS
₹68
Face value
8
Shares outstanding
16,539,015
CFO
₹536.83 Cr
EBITDA
₹731.89 Cr
Net Profit
₹507.00 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
RPG Life Sciences
| -1.2 | 23.1 | 15.8 | 5.5 | 40.0 | 36.2 | 23.9 |
|
BSE Healthcare
| 2.7 | 6.8 | 7.9 | 5.7 | 24.7 | 13.8 | 11.1 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
RPG Life Sciences
| 5.7 | 63.9 | 57.7 | 37.0 | 64.6 | 15.8 | 30.6 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
RPG Life Sciences
|
2,295.0 | 3,799.8 | 707.5 | 115.2 | 17.8 | 19.4 | 33 | -- |
| 2,594.1 | 21,258.3 | 1,339.4 | 356.4 | 33.2 | 23.2 | 59.7 | 12.9 | |
| 46.1 | 11.6 | 6.1 | 0.5 | 4.1 | 5.1 | 22.6 | 1.2 | |
| 699.7 | 17,327.2 | 5,365.6 | 595.0 | 16.6 | 13.3 | 29.1 | 3.4 | |
| 210.4 | 1,411.9 | 287.2 | 43.1 | 16.9 | 16.9 | 32.8 | 5.1 | |
| 1,101.0 | 59,335.6 | 6,812.9 | 889.9 | 19.0 | 17.6 | 66.8 | 11.2 | |
| 161.9 | 21,520.5 | 8,869.1 | -383.1 | 1.0 | -4.2 | -- | 2.6 | |
| 3,407.2 | 7,848.7 | 1,773.8 | 309.8 | 24.0 | 43.1 | 25.3 | 10.1 | |
| 467.7 | 18,887.7 | 3,738.7 | 316.7 | 12.5 | 7.5 | 59.6 | 3.9 | |
| 43.6 | 266.2 | 43.6 | -1.1 | 4.8 | -1 | -- | 2.8 |
No Review & Analysis are available.
RPG Life Sciences Limited, an integrated pharmaceutical company, develops, manufactures, and markets branded formulations, generic, and synthetic active pharmaceutical ingredients (APIs) in India and internationally. The company offers synthetic APIs... in various therapeutic categories, including immunosuppressants, anti-psychotic, anti-anginal, anthelmentics, anti-convulsant, and anti-spasmodic, etc. It also provides generics for immunosuppressant therapy; and finished dosage formulations for various therapies, which include nephrology, rheumatology, oncology, gastroenterology, cardiology, orthopedics, nutritional, diabetology, respiratory, neuropsychiatry, urology, vitamins and minerals, gastrointestinal, pain management, anti-diabetic, gynecology, cardiovascular, pediatrics, neurology, anti-dengue, and dermatology, etc. The company was formerly known as RPG Pharmaceuticals Limited and changed its name to RPG Life Sciences Limited in February 2008. RPG Life Sciences Limited was founded in 1968 and is headquartered in Mumbai, India. RPG Life Sciences Limited is a subsidiary of Nucleus Life Trust. Read more
Incorporated
2007
Chairman
Harsh Goenka
Managing Director
Ashok Nair
Group
RPG Enterprises
Headquarters
Mumbai, Maharashtra
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
Announcements
View AnnouncementsNo News & Announcements are available.
The share price of RPG Life Sciences Ltd is ₹2,295.00 (NSE) and ₹2,297.45 (BSE) as of 30-Apr-2026 IST. RPG Life Sciences Ltd has given a return of 39.95% in the last 3 years.
The P/E ratio of RPG Life Sciences Ltd is 32.99 times as on 30-Apr-2026, a 10 discount to its peers’ median range of 36.61 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
20.56
|
7.10
|
|
2024
|
28.87
|
6.75
|
|
2023
|
17.01
|
3.74
|
|
2022
|
17.98
|
3.62
|
|
2021
|
16.00
|
2.96
|
The 52-week high and low of RPG Life Sciences Ltd are Rs 2,725.00 and Rs 1,733.00 as of 03-May-2026.
RPG Life Sciences Ltd has a market capitalisation of ₹ 3,800 Cr as on 30-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in RPG Life Sciences Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.